The manufacturing project is part of recently received funding from the National Institute of Allergy and Infectious Diseases (NIAID) to offer preclinical development and cGMP manufacturing support for multiple vaccine and biologic products.
As part of the contract, Avid will provide process verification, assay development, robust and compliant process development services.
ABL president and chief executive officer Thomas VanCott said the ABL will advance the NIH program to provide patients with better HIV prevention options.
"Avid has established experience and expertise that we feel will be a great complement to the existing processes for this application," VanCott added.
Avid Bioservices president Steven King said, "HIV continues to be an epidemic for which more prevention strategies are needed and we are enthusiastic about working toward a potential solution in collaboration with ABL and the NIH."